Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Fortune favors the brave

On the front page of its June 2012 edition, the Chinese journal Health News published a poem by Chen Zhu, the minister of health. It read, in part, “The wind and thunder moving health reform across the country herald glad tidings/.../The deep pool is nothing to be afraid of…Heroes dare to cross.” Unorthodox though it was for a strategy memo, it turns out that this call to action may contain good advice for companies.

BMS and ipilimumab: Co-operation with academia and other companies yields success

A new metastatic melanoma product, ipilimumab (sold as Yervoy), from Bristol-Myers Squibb (BMS), has the potential to be a blockbuster. Malignant melanoma is increasing in frequency and this is the first new drug approved for the condition since 1998. Unlike previous treatments, it has been shown to increase life expectancy in patients by several months on average, and 28% are alive after two years, compared with just 14% using the previous treatment. Rather than the story of a single innovation, ipilimumab’s development shows how co-operation can yield a

Value and oncology: a different definition?

Oncology is the therapeutic area in which the value challenge is most acute. According to 41% of survey respondents and 50% of those from drug companies, it is the most difficult area in which to demonstrate value.

In search of value: Shire Pharmaceuticals changes its business model

A decade ago Shire Pharmaceuticals&; business model centred on the improvement and reformulation of existing drugs. The value of these products resulted from marginal improvements to existing forms of the drug or improved compliance through greater ease of use.

Canada's nurse navigators

Canada shares with Australia several characteristics, including population size, wealth and the healthcare challenges posed by geographical vastness. Northern Health, one of six regional health authorities in British Columbia, covers an area nearly the size of France with a population of only about 350,000 people. The challenge it faced was to simplify the steps in the breast cancer field to eradicate unnecessary delays. With limited resources, it is using an innovative mix of stakeholder engagement, technology and multidisciplinary care.

Value and oncology: a different definition?

Oncology is the therapeutic area in which the value challenge is most acute. According to 41% of survey respondents and 50% of those from drug companies, it is the most difficult area in which to demonstrate value.

In search of value: Shire Pharmaceuticals changes its business model

A decade ago Shire Pharmaceuticals' business model centred on the improvement and reformulation of existing drugs. The value of these products resulted from marginal improvements to existing forms of the drug or improved compliance through greater ease of use.

Making aid work

As the international community gathers to discuss the post-2015 development agenda and how best to finance the Sustainable Development Goals, it is important we learn from our mistakes and redress the recipient-donor relationship, says Roger Riddell, an associate at international development consultancy, Oxford Policy Management.

Investing in Quality: Healthcare in the UAE

What are the main quality gaps to be overcome in this period? How are changes such as mandatory insurance laws, management outsourcing of public facilities, regulatory devolution and increased rates of accreditation and data collection influencing quality of care?

This study, based on extensive desk research and interviews with leading experts from government and business, identifies the key healthcare quality challenges and the implications of changes in the health system for service quality.

Drug approvals that get the balance right

The regulation of pharmaceuticals in the US appears to have rotated from tardiness to speed. Yet both have the potential to harm or even kill patients who may already be seriously unwell.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week